Please use a PC Browser to access Register-Tadawul
Get It
Immunitybio Announces Results Of Anktiva Combined With Checkpoint Inhibitors In Non-Small Cell Lung Cancer; Schedules Meeting To Discuss Registration Path For ANKTIVA In Lung Cancer With FDA
ImmunityBio Inc Ordinary Shares -7.84%
ImmunityBio Inc Ordinary Shares IBRX | 2.17 | -7.84% |
- QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy
- Positive results seen in both PD-L1 negative and PD-L1 positive participants with NSCLC
- Data reaffirms the mechanism of action of ANKTIVA as an immune cell enhancer that activates natural killer (NK) cells and memory T cells to rescue checkpoint inhibitor (pembrolizumab, nivolumab, atezolizumab) failures across multiple tumor types
- Meeting scheduled with FDA in June to discuss path to registration filing of ANKTIVA plus checkpoint inhibitors in 2nd- and 3rd-line NSCLC patients whose cancer previously did not respond to checkpoint therapy
- $100 million in non-dilutive cash infusion with ANKTIVA approval brings cash-on-hand to approximately $240 million for launch of ANKTIVA in non-muscle invasive bladder cancer (NMIBC)
- Company has scheduled a conference call to discuss registration plans for NSCLC, status of ANKTIVA launch readiness for NMIBC, and ANKTIVA as the backbone of our clinical trial pipeline for multiple tumor types
